Eleventh International Symposium on Regional Cancer Therapies
Sheraton Wild Horse Pass Resort & Spa
Chandler, Arizona

February 13–15, 2016

UPMC CancerCenter
Partner with University of Pittsburgh Cancer Institute

Sponsored by
David C. Koch
Regional Cancer Therapy Center
and
University of Pittsburgh School of Medicine
Center for Continuing Education in the Health Sciences
and
UPMC Cancer Centers

In Collaboration with
The University of Maryland
Marlene and Stewart Greenebaum Cancer Center
and
The Medical College of Wisconsin
Cancer Center

Course Co-Directors
H. Richard Alexander, MD
Professor of Surgery
University of Maryland Medical Center
Baltimore, Maryland

David L. Bartlett, MD
Professor of Surgery
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Robert P. Edwards, MD
Professor, Obstetrics and Gynecology and Reproductive Services
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

T. Clark Gamblin, MD, MS
Stuart D. Wilson Chair in Surgical Oncology
Chief, Division of Surgical Oncology
Associate Professor of Surgery
Medical College of Wisconsin
Milwaukee, Wisconsin

For additional information or to register online, contact:
https://ccehs.upmc.com

For additional information or to register online, contact:
https://ccehs.upmc.com
Intent and Overview
This course is designed to cover the most recent advances in cancer therapy that are primarily of a regional focus, such as gastrointestinal, intraperitoneal, hepatic, ovarian and thoracic. Upon completion of the activity, learners from several disciplines should be able to discuss the latest regional therapies in surgical oncology.

Who Should Attend
This course is designed for physicians and nurses practicing in the areas of Medical, Surgical, Thoracic and Gynecologic Oncology and Gastroenterology.

Continuing Education Credit
The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Pittsburgh School of Medicine designates this live activity for a maximum of 20.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other health care professionals are awarded 2.0 continuing education units (CEU’s) which are equal to 20.7 contact hours.

Special Needs
Participation by all individuals is encouraged. Advance notification of any special needs will help us provide better service. Please notify us of your needs at least two weeks in advance of the program by calling Maureen Hewko at (412) 623-5993.

Schedule – Saturday, February 13, 2016

6:30 am  Registration and Breakfast
6:45 am  Welcome

Moderators: Steven Ahrendt, MD and Guillermo Flores Ayala, MD

7:00 am  The Comprehensive Complication Index: A New Measure of the Burden of Complications after HIPEC
  Sinziana Dumitra, MD, et. al.

7:15 am  Re-admissions for Delayed Complications after CRS and HIPEC
  Vassiliki Manou, MD, et. al.

7:30 am  Goal-Directed Fluid Management Improves Morbidity Associated with Extended Cytoreduction and HIPEC
  Laura Lambert, MD, et. al.

7:45 am  Repeat CRS and HIPEC for the Treatment of Recurrent Peritoneal Surface Malignancy: Is it Worthwhile?
  Ramy Fouad, MD, et. al.

8:00 am  Delayed Gastric Emptying following CRS and HIPEC
  Lola Chabtini, MD, et. al.

8:15 am  Acute Kidney Injury in Patients Undergoing CRS plus HIPEC
  George Salti, MD, et. al.

8:30 am  Impact of Previous Gynecologic Surgical Procedures on Short Term and Oncological Outcomes in Patients Treated with CRS and HIPEC
  Marcello Guaglio, MD, et. al.

8:45 am  Is Diverting Ostomy Needed in High-Risk Anastomosis During Cytoreductive Surgery and HIPEC?
  Matthew Whealon, MD, et. al.

9:00 am  Impact of Chemotherapy Regimen on Post-Operative Complications After CRS and HIPEC
  Juan Camilo Correa, MD, et. al.

9:15 am  Debate: Repeat CRS/HIPEC for Patients Who Recur within Two Years?
  Moderator: John Kane III, MD
  YES — Kiran Turaga, MD   NO — Konstantinos Votanopoulos, MD

9:45 am  Break
10:00 am  Does Fellowship Training Overcome the Learning Curve in Cytoreductive Surgery and Heated Intraperitoneal Chemoperfusion
   Cameron Schlegel, MD, et. al.

10:15 am  Defining Selection Criteria for Patients with Advanced Peritoneal Carcinomatosis of Colorectal Origin
   C. Komen Brown, MD, et. al.

10:30 am  Impact of Body Mass Index (BMI) on Morbidity and Mortality in Cytoreductive Surgery (CRS) with Intraperitoneal Chemotherapy (IPC)
   Giorgos Karakousis, MD, et. al.

10:45 am  Hepatic Artery Infusion for Recurrent or Chemo Resistant Hepatic Malignancy
   Harold Wanebo, MD, et. al.

11:00 am  Novel Mouse Models of Hepatic Artery Infusion (HAI)
   Minhyung Kim, MD, et. al.

11:15 am  Overall Survival after Ablation for Small Size Hepatocellular Carcinoma at Academic Cancer Centers vs. Community Cancer Centers
   Nicholas Berger, MD, et. al.

11:30 am  Ablation for Small HCC Lesions: Is Chemotherapy Necessary?
   Nicholas Berger, MD, et. al.

11:45 am  Liver Resection Following Selective Internal Radiation Treatment with Yttrium-90: A Bi-Institutional Analysis
   G. Paul Wright, MD, et. al.

Noon  GUEST LECTURER
   Hepatic Artery Infusional Chemotherapy for Primary and Metastatic Cancer
   Michael D’Angelica, MD, FACS

12:30 pm  Break for Lunch

12:45 pm  CASE PRESENTATION AND DISCUSSION
   Discussants: H. Richard Alexander, MD and Nathan Bahary, MD

   Immunotherapy for Peritoneal Carcinomatosis
   Nathan Bahary, MD

   Hepatoid Carcinoma of the Ovary with Peritoneal Metastases Treated with Cytoreductive Surgery and HIPEC
   Samer Naffouje, MD, et. al.

   Unusual Presentation of Pseudomyxoma Peritonei
   Amy Schulze, MD, et. al.

   Intrauterine Metastases of Appendiceal Tumors Impact Cytoreduction
   Jessica Cintolo-Gonzalez, MD, et. al.

   Cytoreductive Surgery and HIPEC for Sarcomatosis from Uterine Adenosarcoma
   Michael O’Leary, MD, et. al.

   Peritoneal Recurrent Fibrolamellar Hepatocellular Carcinoma Treated with CRS and HIPEC
   David Brown, MD, et. al.

1:45 pm  Saturday Session Adjournment

6:00 pm  Poster Sessions

7:00 pm  MEET THE PROFESSOR RECEPTION
   Presentation of Gabriella Graham Patient Advocate Award by Laura Lambert, MD

Schedule – Sunday, February 14, 2016

6:30 am  Registration and Breakfast

6:45 am  Welcome

   Moderators: Jason Foster, MD and Matthew Holtzman, MD

7:00 am  Recurrence of Malignant Peritoneal Mesothelioma: Insights Based on Standardized Second Look Procedures
   Michael Kluger, MD, et. al.
7:15 am  Peritoneal Surface Oncology Group International Registry on Peritoneal Mesothelioma  
Marcello Deraco, MD, et. al.

7:30 am  Outcomes of Well-Differentiated Papillary Peritoneal Mesothelioma  
Garrett Nash, MD, et. al.

7:45 am  Nomogram to Predict Overall Survival in Diffuse Malignant Peritoneal Mesothelioma: A Peritoneal Surface Oncology Group International (PSOGI) Multicenter Study  
Shigeki Kusamura, MD, et. al.

8:00 am  Long-term Combined Intraperitoneal and Systemic Chemotherapy for Patients with Malignant Mesothelioma Results in Improved Survival  
Paul Sugarbaker, MD, et. al.

8:15 am  Dual Cavity Malignant Mesothelioma: Presentation and Survival  
Yaakov Bressler, MD, et. al.

8:30 am  Analysis of Outcomes in Young Patients (≤ 50 y) with Malignant Peritoneal Mesothelioma Treated with Cytoreductive Surgery and HIPEC  
Julie Terhune, MD, et. al.

8:45 am  Predicting Risk of Peritoneal Recurrence in Stage II Colon Cancer: Secondary Analysis of CALGB9581 Trial  
Rahul Rajeev, MD, et. al.

9:00 am  Multimodality Therapy for Peritoneal Metastases from Epithelial Ovarian Cancer  
Deepa Magge, MD, et. al.

9:15 am  GUEST LECTURER  
Scientific Basis for CRS and HIPEC in the Treatment of Peritoneal Metastases: A Historical Perspective  
Paul Sugarbaker, MD

9:45 am  Break/Exhibitors/Posters

Moderators: Robert Edwards, MD and Marcello Deraco, MD

10:00 am  Perioperative Systemic Chemotherapy for Peritoneal Mucinous Appendiceal Carcinomas Treated with Cytoreductive Surgery and HIPEC  
John Spiliotis, MD, et. al.

10:15 am  Multi-institution Review of the Role of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy in Metastatic Gastric Adenocarcinoma in the U.S.  
Laura Enomoto, MD, et. al.

10:30 am  Management of Peritoneal Carcinomatosis of a Colonic Origin: Role of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: A Single Institution’s Experience over Two Decades  
Chukwuemeka Ihemelandu, MD, et. al.

10:45 am  Cytoreductive Surgery and HIPEC: Can We Improve Survival with Less Postoperative Complications?  
Mecker Moller, MD, et. al.

11:00 am  Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Metastases Combined with Curative Surgery for Hematogenous Metastases: Analysis of Early and Long-Term Outcomes  
Dario Baratti, MD, et. al.

11:15 am  Peritoneectomy Procedures Combined with HIPEC in Advanced Ovarian Cancer Retrospective Italian National Multicenter Observational Study: Update of 503 Cases  
Paolo Sammartino, MD, et. al.

11:30 am  Histologic Predictors of Recurrence in Mucinous Appendiceal Tumors with Peritoneal Dissemination After HIPEC  
Joel Baumgartner, MD, et. al.

11:45 am  Cytoreductive Surgery and HIPEC in the Management of Uterine Sarcoma (US) with Peritoneal Dissemination (PD)  
Armando Sardi, MD, et. al.

Noon  GUEST LECTURER  
New Advances in the Immunotherapy of Ovarian Cancer  
Adekunle Odunsi, MD, PhD

12:30 pm  Lunch
1:00 pm  PROPOSED AND ONGOING CLINICAL TRIALS
Discussants: Charles Staley, MD and Jesus Esquivel, MD

Assessment of Pre-Operative PCI Scoring with Integrated PET-DWI-MRI in Patients with Peritoneal Carcinomatosis: A Feasibility Pilot Study in Development
Daniel Labow, MD, et. al.

A Minimally Invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy
Kaitlyn Kelly, MD, et. al.

A Phase I Clinical Trial of Bi-Directional Chemotherapy for Unresectable Appendiceal or Colon Cancer
Bradley Switzer, MD, et. al.

A Phase II Study to Evaluate Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma with Peritoneal Carcinomatosis
Joel Baumgartner, MD, et. al.

The Role of Second-Look Laparoscopy in Patients at Risk of Recurrent Peritoneal Carcinomatosis
Yahel Agmon, MD, et. al.

Phase I/II Trial Evaluating aDCI Vaccines Combined with Tumor-selective Chemokine Modulation as Adjuvant Therapy after Surgical Resection of Peritoneal Surface Malignancies
Mark Girgis, MD

Update on ICARUS: A Randomized Trial of Intraperitoneal Chemotherapy After CRS for Appendiceal or Colorectal Carcinoma
Garrett Nash, MD

Prospective Randomized Trial Comparing Mitomycin and Oxaliplatinum in the Perfusate of Patients Undergoing HIPEC for Cancer of Appendix
Edward Levine, MD

2:00 pm  Sunday Session Adjournment
6:00 pm  Poster Viewing
7:00 pm  ASPSM Meeting

Schedule – Monday, February 15, 2016
6:30 am  Registration and Breakfast
6:45 am  Welcome

7:00 am  Pulmonary Suffusion for Oligometastatic Malignancies
Todd Demmy, MD, et. al.

7:15 am  BrachyVAC Treatment of Superficial Malignancies: Results of a Consecutive Case Series
Mark Goodman, MD, et. al.

7:30 am  Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared to Isolated Limb Perfusion for In-Transit Melanoma Metastases
Lesly Dossett, MD, et. al.

7:45 am  Electrochemotherapy in Locally Advanced Melanoma and Non-Melanoma Skin Cancer: Experience from a Single Institution
Alessandro Testori, MD, et. al.

8:00 am  Inflammation-based Prognostic Scores; Utility in Prognostication and Patient Selection for Cytoreduction and Perioperative Intraperitoneal Chemotherapy in Patients with PC of a Colonic Origin
Yutaka Yonemura, MD, et. al.

8:15 am  Aminolevulinic acid (ALA) is a Promising Compound for Detection of Small Peritoneal Metastases: ALA Guided Cytoreductive Surgery
Chukwumeka Ihemelandu, MD, et. al.

8:30 am  A Comparison of Appendectomy Only vs. Cytoreductive Surgery and HIPEC in 59 Patients with Early Stage Mucinous Appendiceal Neoplasms
Jesus Esquivel, MD

8:45 am  A Comprehensive Evaluation of Barriers to Referral of Patients for Cytoreductive/HIPEC
Valerie Francescutti, MD, et. al.

9:00 am  A Snapshot of CS/HIPEC Perioperative Care Practice Patterns Around the World: On the Pathway to Success or Opportunity for Improvement
Allison Maciver, MD, et. al.

9:15 am  Prognostic Factors and Significance of Gastrointestinal Leak after Cytoreductive Surgery (CRS) with Heated Intraperitoneal Chemotherapy (HIPEC)
Konstantinos Chouliaras, MD, et. al.

9:30 am  GUEST LECTURER
The Genetics of Peritoneal Surface Malignancies: Insights and Opportunities
Andrew Lowy, MD

10:00 am  Break/Exhibitors/Posters
Moderators: James Pingpank, MD and Brian Loggie, MD

10:15 am  Multimodality Approach to Peritoneal Metastases: 1312 Patients Treated by a Multi-Disciplinary Team
Haroon Choudry, MD, et. al.

10:30 am  Molecular Profiling: Prognostic Biomarkers in Patients Presenting with Peritoneal Carcinomatosis of the Appendix and Colon Treated with Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy
Chukwuemeke Ihemelanda, MD, et. al.

10:45 am  Single-Port Access for Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC): Feasibility and Safety
Michele DeSimone, MD, et. al.

11:00 am  MDM-2 Overexpression in Human Stem-like and Mature Colon Cancer Cells as a Target for Anti-Cancer Therapy: Steps Toward a Translational Model
Mohammad Shaikh, MD, et. al.

11:15 am  The Use of a pH-activated Indocyanine Green-Encoded Nanosensor (PINS) for Detection of Peritoneal Disease
Glen Balch, MD, et. al.

11:45 am  Exploration of Mutations in GI Cancers with Peritoneal Metastasis
Asish Patel, MD, et. al.

Noon  Preclinical Evaluation of Cathepsin-Based Fluorescent Imaging System for Cytoreductive Surgery
Carlos HF Chan, MD, et. al.

12:15 pm  Molecular Profiling of Appendix-Derived Pseudomyxoma Peritonei (PMP)
Elizabeth Glieson, MD, et. al.

12:30 pm  Analysis of Twenty Years of Reporting on Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancers: Proposal for Standardized Reporting
Samer Naffouje, MD, et. al.

12:45 pm  Break for Lunch

12:55 pm  Announcement and Presentation of Poster Award Winners

1:00 pm  Conference Adjournment

---

Poster Presentations

1. The Effect of Perfusate Buffering on Toxicity and Response in Isolated Hepatic Perfusion for Uveal Melanoma Metastases – Ilan Ben-Shabat, MD, et. al.

2. The Potential Impact of Host Murine Granulocytes on Growth of Human Appendiceal Cancer – Laura Lambert, MD, et. al.


4. A Novel Approach to Diaphragm Resection in Cytoreductive Surgery – Cameron Schlegel, MD, et. al.

5. A Phase II Randomized Study: Outcomes after Cytoreductive Surgery (CRS) with or without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) followed by Adjuvant Chemotherapy as Initial Treatment – Armando Sardi, MD, et. al.

6. BRAF Status as a Predictive Factor for Response in Isolated Limb Perfusion – Ilan Ben-Shabat, MD, et. al.

7. Intensive Care Unit Hospitalization after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) – John Spiliotis, MD, et. al.

8. Creating a Primary Regional Referral Center for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) – Easue Chang, MD, et. al.

9. CEA Level Predicts Oncologic Outcomes Following Surgical Resection of Colorectal Peritoneal Metastases – G. Paul Wright, MD, et. al.

10. Does Upfront Therapy with Cytoreductive Surgery and HIPEC Confer a Survival Benefit in Patients with Synchronous Gastric Peritoneal Carcinomatosis when Compared with Patients with Metachronous Gastric Peritoneal Carcinomatosis. – Nikolaos Kopanakis, MD, et. al.


15. Impact of KRAS/BRAF Mutations in Patients with Colorectal Peritoneal Metastases - G. Paul Wright, MD, et. al.


17. Predictors of Palliative Care Consultation in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) – Rachel Morris, MD, et. al.

18. Trends in Utilization of CRS and HIPEC for Peritoneal Malignancies – Kazi Ullah, MD, et. al.


20. Let’s Agree to Agree: Unification of Practice Among High-Volume CS/HIPEC Surgeons in the United States – Eisar Al-Sukhni, MD, et. al.

21. Regional Therapy for Isolated Peritoneal Metastases from Small Bowel and Upper Gastrointestinal Malignancies – Deepa Magge, MD, et. al.

22. Same Day Extubation After Cytoreductive Surgery and HIPEC – Hatem Halabi, MD, et. al.

**Course Co-Directors**

**H. Richard Alexander, MD**  
Professor of Surgery  
University of Maryland School of Medicine  
Baltimore, MD

**David L. Bartlett, MD**  
Professor of Surgery  
University of Pittsburgh School of Medicine

**Robert P. Edwards, MD**  
Professor, Obstetrics, Gynecology and Reproductive Sciences  
University of Pittsburgh School of Medicine

**T. Clark Gamblin, MD, MS**  
Stuart D. Wilson Chair in Surgical Oncology  
Medical College of Wisconsin  
Milwaukee, WI

**Invited Faculty**

**Steven Ahrendt, MD**  
Associate Professor of Surgery  
University of Pittsburgh School of Medicine

**Guillermo Flores Ayala, MD**  
Instituto Jalisciense de Cancerologia  
Guadalajara, Mexico

**Nathan Bahary, MD**  
Associate Professor of Medicine  
University of Pittsburgh School of Medicine

**Glen Balch, MD**  
Assistant Professor of Surgery  
University of Texas  
Dallas, TX

**Joel Baumgartner, MD**  
UCSD Moores Cancer Center  
La Jolla, CA

**Andrew Lowy, MD**  
Professor of Surgery  
UC San Diego Medical Center  
School of Medicine  
La Jolla, CA

**Adekunle Odunsi, MD, PhD**  
Cancer Center Deputy Director  
The M. Steven Piver Professor and Chair  
Department of Gynecologic Oncology  
Executive Director, Center for Immunotherapy  
Roswell Park Cancer Institute  
New York, NY

**Paul H. Sugarbaker, MD**  
Director, Program in Peritoneal Surface Malignancy  
Washington Hospital Centre  
Washington, DC

**Guest Faculty**

**Michael D’Angelica, MD, FACS**  
Enid A. Haupt Chair in Surgery, Memorial Sloan Kettering Cancer Center  
Attending Surgeon, Hepatopancreatobiliary Service, Memorial Sloan Kettering Cancer Center  
Program Director, Complex Surgical Oncology and HPB Fellowship  
Professor of Surgery, Cornell University, Weill Medical College  
New York, NY
All individuals in a position to control the content of this education activity are required to disclose all relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

Faculty reside in the Pittsburgh, Pennsylvania, metropolitan area unless indicated otherwise.

The University of Pittsburgh is an affirmative action, equal opportunity institution.
Elizabeth Gleeson, MD  
Drexel University College of Medicine  
Philadelphia, PA

Mark Goodman, MD  
University of Pittsburgh Medical Center  
Pittsburgh, PA

Marcello Guaglio, MD  
Foundazione IRCCS Instituto  
Nazionale dei Tumori  
Milano, Italy

Whitney Guerrero, MD  
University of Tennessee Health Center  
Memphis, TN

Hatem Halabi, MD  
Cancer Treatment Centers of America  
Zion, IL

Chukwuemeka Ihemelandu, MD  
MedStar Washington Hospital Center  
Washington, DC

Giorgos Karakousis, MD  
Hospital of the University of Pennsylvania  
Philadelphia, PA

Kaitlyn Kelly, MD  
University of California, San Diego  
La Jolla, CA

Minhyung Kim, MD  
Roswell Park Cancer Institute  
Buffalo, NY

Michael Kluger, MD  
Columbia College of Physicians and  
Surgeons  
New York, NY

Nikolaos Kopanakis, MD  
Metaxa Cancer Center  
Piraeus, Greece

Shigeki Kusamura, MD  
Milan Tumor Institute  
Milano, Italy

Allison Maciver, MD  
Roswell Park Cancer Institute  
Buffalo, NY

Deepa Magge, MD  
University of Pittsburgh Medical Center  
Pittsburgh, PA

Vasiliki Manou, MD  
Metaxa Cancer Hospital  
Piraeus, Greece

Mecker Moller, MD  
University of Miami Miller School of  
Medicine  
Miami, FL

William Morano, MD  
Drexel University College of Medicine  
Philadelphia, PA

Rachel Morris, MD  
Medical College of Wisconsin  
Milwaukee, WI

Samer Naffouje, MD  
University of Illinois at Chicago  
Chicago, IL

Michael O’Leary, MD  
City of Hope National Medical Center  
Duarte, CA

Asish Patel, MD  
University of Nebraska Medical Center  
Omaha, NE

Rahul Rajeev, MD  
Medical College of Wisconsin  
Milwaukee, WI

George Salti, MD  
University of Illinois at Chicago and Edward  
Cancer Center  
Chicago, IL

Paolo Sammartino, MD  
Sapienza University of Rome  
Rome, Italy

Armando Sardi, MD  
Mercy Medical Center  
Baltimore, MD

Cameron Schlegel, MD  
Vanderbilt University  
Nashville, TN

Amy Schulze, MD  
Indiana University School of Medicine  
Indianapolis, IN

Mohammad Shaikh, MD  
Drexel University College of Medicine  
Philadelphia, PA

Simone Sibio, MD  
University of Rome  
Rome, Italy

John Spiliotis, MD  
Metaxa Cancer Hospital  
Piraeus, Greece

Bradley Switzer, MD  
University of Massachusetts  
Worcester, MA

Julie Terhune, MD  
University of Maryland  
Baltimore, MD

Alessandro Testori, MD  
Istituto Europeo di Oncologia  
Milano, Italy

Gregory Tiesi, MD  
University of Miller School of Medicine  
Miami, FL

Kazi Ullah, MD  
SUNY Stony Brook  
Stony Brook, NY

Harold Wanebo, MD  
Roger Williams Medical Center  
Bristol, RI

Matthew Whealon, MD  
University of California Irvine  
Orange, CA

G. Paul Wright, MD  
University of Pittsburgh Medical Center  
Pittsburgh, PA

Yutaka Yonemura, MD  
Kishiwada Tokushukai Hospital  
Kyou, Japan
**Registration Information**

Online Registration is accepted until **February 12, 2016**. After this date, you are only able to register for the conference on site.

Registering online is the quickest and easiest way to reserve your space at CCEHS conferences.

Visit our online registration site at [https://ccehs.upmc.com](https://ccehs.upmc.com). Scroll down to the *Eleventh International Symposium on Regional Cancer Therapies* section on the web page.

- Click the registration button and enter all of the requested information.
- After registering, an electronic confirmation will be sent to the email address you provided when you registered.

Registration is not complete until you receive the confirmation email for your preregistration. If you do not receive this letter within 5-7 days of registration, please contact Maureen Hewko at (412) 623-5993.

**You must bring this confirmation with you to the conference.**

**Registration Cancellation**

All cancellations must be in writing and sent to us via US mail, email or fax. Tuition cancellations postmarked or date stamped before **January 13, 2016** will be completely refunded. After **January 13, 2016**, a $35 administrative fee will be assessed. No refunds will be made after **February 1, 2016**.

Conference contact for cancellation requests:

Maureen Hewko, MBA
UPMC Cancer Pavilion 413, 5150 Centre Avenue
Pittsburgh, PA 15232
Email: hewkom@upmc.edu • Telephone: (412) 623-5993
Fax: (412) 692-2520

**Registration Fees**

- $350 Physicians and researchers
- $250 Nurses and other health care professionals

**Registration fee includes:**

- Continuing education credit
- Registration and course materials
- Continental breakfast, refreshments and a light lunch
- If interested, workshops on Sunday afternoon.

**Meeting Location**

The conference will be held at the *Sheraton Wild Horse Resort*. Conference reservations are at the sole responsibility of the attendees who may contact the hotel.

If registering for a room at the hotel online, please go to [http://www.regionaltherapies.com](http://www.regionaltherapies.com) and click on conference information.

If you wish to make your reservation by phone, please call 520-796-8278 and mention that you are with the UPMC group.

The cut-off date for reserving a room at the discounted rate of $234 per night is **January 13, 2016**.

**Accommodations**

Nightly Guest Room Rate: **$234** per night

*Note: Resorts room rates are subject to additional taxes and resort fees as applicable.*

**Transportation**

If you are flying to the conference, the closest airport to the Sheraton is the Phoenix International Airport. Please go to [www.regionaltherapies.com](http://www.regionaltherapies.com) for information about transportation from the airport.

**For additional information, contact:**

Maureen Hewko, MBA
Telephone: (412) 623-5993
Fax: (412) 692-2520
Email: hewkom@upmc.edu
Koch Center Website: [http://www.regionaltherapies.com](http://www.regionaltherapies.com)

**Visit the Center for Continuing Education in the Health Sciences Web Site**

Our Internet address is: [https://ccehs.upmc.com](https://ccehs.upmc.com)

The UPMC Center for Continuing Education in the Health Sciences invites you to visit our web location. Receive information on CME programs, earn CME credits on the Internet, and access information about our formal courses and much more. Discover who we are and how you can contact us. Please visit our web location often to get updated information on upcoming programs.